Molecular Docking Study on Dipeptidyl Peptidase-4 Inhibitors.

Simple item page
dc.contributor.authorAnitha, K
dc.contributor.authorGopi, G
dc.contributor.authorGirish
dc.contributor.authorKumar, P Senthil
dc.date.accessioned2013-09-16T06:50:11Z
dc.date.available2013-09-16T06:50:11Z
dc.date.issued2013-08
dc.description.abstractDipeptidyl peptidase (DPP)-IV inhibitors are a new approach to the treatment of type 2 diabetes. DPP-IV is a member of a family of serine peptidases that includes quiescent cell proline dipeptidase (QPP), DPP8, and DPP9. DPP-IV is a key regulator of incretin hormones, but the functions of other family members are unknown. To determine the importance of selective DPP-IV inhibition for the treatment of diabetes, we conducted molecular docking studies on clinical inhibitors of DPP-IV.en_US
dc.identifier.citationAnitha K, Gopi G, Girish, Kumar P Senthil. Molecular Docking Study on Dipeptidyl Peptidase-4 Inhibitors. International Journal of Research and Development in Pharmacy and Life Sciences. 2013 Aug-Sept; 2(5): 602-610.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/148290
dc.language.isoenen_US
dc.source.urihttps://www.ijrdpl.com/docs/currentissue%20aug%20sept%202013/12.pdfen_US
dc.subjectDPP IVen_US
dc.subjectDockingen_US
dc.subjectType 2 diabetesen_US
dc.subjectAutoDocken_US
dc.titleMolecular Docking Study on Dipeptidyl Peptidase-4 Inhibitors.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijrdpl2013v2i5p602.pdf
Size:
660.79 KB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
International Journal of Research and Development in Pharmacy and Life Sciences